SB
Samsara BioCapital Portfolio holdings
AUM
$489M
This Quarter Return
+5.61%
1 Year Return
+135.25%
3 Year Return
+909.96%
5 Year Return
+774.56%
10 Year Return
–
AUM
$489M
AUM Growth
+$489M
(-13%)
Cap. Flow
-$42.5M
Cap. Flow
% of AUM
-8.69%
Top 10 Holdings %
Top 10 Hldgs %
88.2%
Holding
39
New
2
Increased
1
Reduced
9
Closed
10
Top Buys
| 1 |
Aura Biosciences
AURA
|
$6.26M |
| 2 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$5.31M |
| 3 |
ALMS
Alumis Inc. Common Stock
ALMS
|
$4.6M |
Top Sells
| 1 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$7.66M |
| 2 |
UPB
Upstream Bio, Inc. Common Stock
UPB
|
$6.85M |
| 3 |
SLRN
ACELYRIN
SLRN
|
$6.23M |
| 4 |
Bolt Biotherapeutics
BOLT
|
$5.75M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
$5.54M |
Sector Composition
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Scholar Rock
SRRK
$3.14B
| $199M | 40.66% | 5,612,896 | – | – |
|
2
Mineralys Therapeutics
MLYS
$1.03B
| $76.8M | 15.7% | 5,674,916 | – | – |
|
|
SEPN
3
Septerna, Inc. Common Stock
SEPN
$539M
| $33.3M | 6.81% | 3,149,128 | – | – |
|
|
KLRS
4
Kalaris Therapeutics, Inc. Common Stock
KLRS
$76.3M
| $30.6M | 6.25% | 11,448,081 | – | – |
|
5
Neurogene
NGNE
$264M
| $25.7M | 5.25% | 1,717,127 | – | – |
|
|
CRGX
6
DELISTED
CARGO Therapeutics
CRGX
| $18.2M | 3.72% | 4,415,689 | – | – |
|
|
UPB
7
Upstream Bio, Inc. Common Stock
UPB
$923M
| $15.8M | 3.24% | 1,443,231 -623,915 | -30% | -$6.85M |
|
|
ALMS
8
Alumis Inc. Common Stock
ALMS
$479M
| $14.4M | 2.95% | 4,801,370 +1,534,872 | +47% | +$4.6M |
|
|
LENZ
9
LENZ Therapeutics
LENZ
$1.1B
| $10.1M | 2.06% | 343,012 -183,378 | -35% | -$5.37M |
|
|
PVLA
10
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $7.66M | 1.57% | 339,743 -339,743 | -50% | -$7.66M |
|
11
Gossamer Bio
GOSS
$562M
| $7.54M | 1.54% | 6,130,268 | – | – |
|
12
Arcellx
ACLX
$3.85B
| $6.68M | 1.37% | 101,457 -33,819 | -25% | -$2.23M |
|
|
13
Aura Biosciences
AURA
$389M
| $6.26M | 1.28% | +1,000,000 | New | +$6.26M |
|
14
Nkarta
NKTX
$151M
| $6.25M | 1.28% | 3,768,035 | – | – |
|
|
AVDL
15
Avadel Pharmaceuticals
AVDL
$1.43B
| $5.98M | 1.22% | 675,504 -292,023 | -30% | -$2.58M |
|
|
JBIO
16
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $5.31M | 1.09% | +531,163 | New | +$5.31M |
|
17
Zymeworks
ZYME
$1.12B
| $3.89M | 0.8% | 310,300 -356,367 | -53% | -$4.47M |
|
|
18
Rhythm Pharmaceuticals
RYTM
$6.85B
| $3.19M | 0.65% | 50,476 -87,642 | -63% | -$5.54M |
|
19
vTv Therapeutics
VTVT
$42.5M
| $3.1M | 0.63% | 206,784 | – | – |
|
|
CTNM
20
Contineum Therapeutics
CTNM
$293M
| $2.34M | 0.48% | 588,816 | – | – |
|
21
Surrozen
SRZN
$104M
| $2.16M | 0.44% | 241,400 | – | – |
|
22
Sutro Biopharma
STRO
$72.7M
| $1.57M | 0.32% | 2,196,814 | – | – |
|
23
Tango Therapeutics
TNGX
$747M
| $1.08M | 0.22% | 210,000 -420,000 | -67% | -$2.15M |
|
24
HilleVax
HLVX
$105M
| $795K | 0.16% | 399,637 | – | – |
|
25
Terns Pharmaceuticals
TERN
$609M
| $755K | 0.15% | 202,348 | – | – |
|